Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton Syndrome
Trial details
- Registry ID
- NCT07538583
- Drugs studied
- QRX003
TrialRedline tracks 4 clinical trials sponsored by Quoin Pharmaceuticals: 4 Phase 2 / 3.
Company identity has not yet been verified
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| Phase 2/3 Clinical Study of QRX003 Lotion in Subjects With Netherton SyndromeNCT07538583 | QRX003 | Recruiting | 2027-01-31Estimated |
| Open Label, Safety and Efficacy Study of QRX003 Lotion in Subjects With Netherton SyndromeNCT05789056 | QRX003, 4% Lotion | Recruiting | 2026-12-30Estimated |
| Clinical Study of QRX003 Lotion in Subjects With Netherton SyndromeNCT06953466 | QRX003, 4% Lotion | Recruiting | 2026-12-30Estimated |
| Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton SyndromeNCT05521438 | QRX003-2% Lotion, QRX003-4% Lotion BID, QRX003-4% Lotion QAM, Vehicle | Active not recruiting | 2025-12-30Actual |
Names as written in the registry records.
NCT06953466 · Quoin Pharmaceuticals
Before: 30 Jul 2026. After: 30 Dec 2026.
NCT05789056 · Quoin Pharmaceuticals
Before: 30 Dec 2025. After: 30 Dec 2026.
NCT05521438 · Quoin Pharmaceuticals
Before: Estimated. After: Actual.
Before: 31 Dec 2025. After: 30 Dec 2025.